According to Zacks, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other equities research analysts have also issued reports on the stock. Roth Capital reissued a neutral rating and set a $71.00 target price (down previously from $87.00) on shares of bluebird bio in a research note on Monday, February 6th. Maxim Group set a $87.00 target price on shares of bluebird bio and gave the company a buy rating in a research note on Friday, February 3rd. Jefferies Group LLC reissued a buy rating and set a $88.00 target price on shares of bluebird bio in a research note on Tuesday, January 10th. Cantor Fitzgerald reissued a sell rating on shares of bluebird bio in a research note on Saturday, December 10th. Finally, J P Morgan Chase & Co reissued a buy rating and set a $120.00 target price on shares of bluebird bio in a research note on Wednesday, December 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company’s stock. bluebird bio has an average rating of Buy and an average price target of $84.36.
Shares of bluebird bio (NASDAQ:BLUE) opened at 76.45 on Thursday. The stock’s market cap is $2.85 billion. bluebird bio has a 52 week low of $35.37 and a 52 week high of $79.70. The stock’s 50 day moving average price is $69.20 and its 200 day moving average price is $62.42.
“bluebird bio, Inc. (BLUE) Downgraded by Zacks Investment Research” was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are reading this report on another website, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this report can be viewed at http://sleekmoney.com/bluebird-bio-inc-blue-downgraded-by-zacks-investment-research/1659502.html.
In related news, insider Jason Cole sold 549 shares of bluebird bio stock in a transaction on Thursday, January 5th. The shares were sold at an average price of $67.10, for a total value of $36,837.90. Following the transaction, the insider now owns 9,389 shares in the company, valued at approximately $630,001.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Davidson sold 6,000 shares of bluebird bio stock in a transaction on Friday, January 27th. The stock was sold at an average price of $69.02, for a total transaction of $414,120.00. Following the completion of the transaction, the insider now owns 14,677 shares in the company, valued at approximately $1,013,006.54. The disclosure for this sale can be found here. Insiders sold a total of 15,549 shares of company stock worth $1,121,368 in the last quarter. Insiders own 3.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Fund Management S.A. increased its position in bluebird bio by 1,233.8% in the second quarter. Capital Fund Management S.A. now owns 6,803 shares of the company’s stock valued at $295,000 after buying an additional 7,403 shares during the last quarter. CAM Group Holding A S increased its position in bluebird bio by 28.0% in the second quarter. CAM Group Holding A S now owns 6,400 shares of the company’s stock valued at $277,000 after buying an additional 1,400 shares during the last quarter. Emerald Acquisition Ltd. bought a new position in bluebird bio during the second quarter valued at about $255,000. JPMorgan Chase & Co. increased its position in bluebird bio by 43.0% in the second quarter. JPMorgan Chase & Co. now owns 85,235 shares of the company’s stock valued at $3,690,000 after buying an additional 25,612 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its position in bluebird bio by 25.3% in the second quarter. Teacher Retirement System of Texas now owns 5,114 shares of the company’s stock valued at $221,000 after buying an additional 1,034 shares during the last quarter.
bluebird bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/bluebird-bio-inc-blue-downgraded-by-zacks-investment-research/1659502.html
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.